Approximately 110 participants enrolled in randomized, double-blind, placebo-controlled study; topline results expected in the second quarter of 2027 MIAMI, Oct. 7, 2026 /PRNewswire/ -- Resolve Therapeutics, a clinical-stage biopharmaceutical company developing non-immunosuppressive...